Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27769629 | 0.97 | HDAC1 (0.57) | HDAC1HDAC2TDP1CHRM1AKR1A1 | |
| SCHEMBL12559160 | 0.89 | CA2 (0.54) | HDAC1HDAC2TDP1CHRM1AKR1A1 | |
| SCHEMBL17244095 | 0.89 | HDAC1 (0.50) | HDAC1HDAC2TDP1CHRM1AKR1A1 | |
| SCHEMBL5377086 | 0.88 | — | — | |
| SCHEMBL13636208 | 0.88 | — | — | |
| SCHEMBL13398634 | 0.87 | HDAC7 (0.48) | HDAC1HDAC2TDP1CHRM1AKR1A1 | |
| SCHEMBL20440700 | 0.87 | HDAC7 (0.48) | HDAC1HDAC2TDP1CHRM1AKR1A1 | |
| SCHEMBL14203373 | 0.87 | HDAC7 (0.48) | HDAC1HDAC2TDP1CHRM1AKR1A1 | |
| SCHEMBL795764 | 0.87 | HDAC7 (0.48) | HDAC1HDAC2TDP1CHRM1AKR1A1 | |
| SCHEMBL28193296 | 0.87 | HDAC7 (0.48) | HDAC1HDAC2TDP1CHRM1AKR1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114354803-B | Method for detecting related substances of sodium valproate oral solution | 成都倍特得诺药业有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-114354803-A | Method for detecting related substances of sodium valproate oral solution | 成都倍特药业股份有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-118373735-B | Valproic acid prepared by cyanoacetic acid ester method | 湖南省湘中制药有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-118373735-A | Valproic acid prepared by cyanoacetic acid ester method | 湖南省湘中制药有限公司 | 2024-07-23 | — | — | CN | disclosed |
| US-20240216514-A1 | NOVEL ANTITUMOR COMPOUNDS AND RELATED METHODS OF MANUFACTURE AND USE | KLOTHO THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216514-A1 | NOVEL ANTITUMOR COMPOUNDS AND RELATED METHODS OF MANUFACTURE AND USE | KLOTHO THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| CN-118010875-A | Detection method for impurities in valproic acid prepared by diethyl malonate method | 湖南省湘中制药有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-114354803-B | Method for detecting related substances of sodium valproate oral solution | 成都倍特得诺药业有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230345815-A1 | METAL-ORGANIC COORDINATION COMPOUND AND METHOD FOR PRODUCING THE SAME | BEEOLED GMBH (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20230330059-A1 | 3-PHENYL-2H-CHROMENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S, CONTAINING SAME | NEUROBIONET, INC. (KR) | 2023-10-19 | — | — | US | disclosed |
| CN-116867781-A | Imidazo [1,2-a ] pyridine derivatives as IRAK4 inhibitors and their use in the treatment of diseases | 渤健马萨诸塞州股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2007075555-A2 | COMBINATION OF AN H3 ANTAGONIST/INVERSE AGONIST AND AN APPETITE SUPPRESSANT | SCHERING CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007067537-A1 | PYRROLOPYRIDINE KINASE INHIBITING COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070048379-A1 | Valproate tablet | GUO MINTONG | 2007-03-01 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-5075486-A | Heating N-/1-propyl-n-butyl/formamide in absence of oxygen wit h alkali metal/silica gel catalyst | SANOFI (FR) | 1991-12-24 | — | — | US | disclosed |
| EP-0308325-B1 | PROCESS FOR THE PREPARATION OF DI-N-PROPYL ACETONITRILE | SANOFI (FR) | 1991-12-11 | — | — | EP | disclosed |
| EP-0308325-A1 | Process for the preparation of di-N-propyl acetonitrile | SANOFI (FR) | 1989-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330059-A1 | 3-PHENYL-2H-CHROMENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S, CONTAINING SAME | APP, BACE1, MAPT | HDAC1 372/4885HDAC2 278/4885TDP1 1835/4885 |
| US-20230345815-A1 | METAL-ORGANIC COORDINATION COMPOUND AND METHOD FOR PRODUCING THE SAME | LIG1, AOC1, ORC3 | HDAC1 80/4885HDAC2 375/4885TDP1 3236/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | HDAC1 444/4885HDAC2 509/4885TDP1 1869/4885 |
| US-20240216514-A1 | NOVEL ANTITUMOR COMPOUNDS AND RELATED METHODS OF MANUFACTURE AND USE | BID, TBCA, PTBP3 | HDAC1 1082/4885HDAC2 1518/4885TDP1 1496/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | HDAC1 3718/4885HDAC2 4191/4885TDP1 3248/4885 |
| US-20070048379-A1 | Valproate tablet | CACNA1A, SUCLG2, CACNA1G | HDAC1 58/4885HDAC2 10/4885TDP1 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.